Zobrazeno 1 - 10
of 85
pro vyhledávání: '"D. Sadi"'
Publikováno v:
Cell Transplantation, Vol 15 (2006)
The development of new cell replacement strategies using neural stem cells (NSC) may provide an alternative and unlimited cell source for clinical neural transplantation in neurodegenerative diseases such as Parkinson's and Huntington's disease. The
Externí odkaz:
https://doaj.org/article/0170b178f83846ff9c16e94a238628b9
Publikováno v:
Cell Transplantation, Vol 11 (2002)
Optimal placement of intrastriatal dopaminergic grafts is likely crucial to optimize clinical recovery in Parkinson's disease (PD). The target sites of dopaminergic grafts vary among clinical trials and may partially explain the variable results in c
Externí odkaz:
https://doaj.org/article/7fbe381eddb6457aa29d41f110c2cd1b
Publikováno v:
Cell Reports, Vol 7, Iss 6, Pp 1755-1761 (2014)
SummaryTo determine the long-term health and function of transplanted dopamine neurons in Parkinson’s disease (PD) patients, the expression of dopamine transporters (DATs) and mitochondrial morphology were examined in human fetal midbrain cellular
Autor:
Arindom Sen, Ivar Mendez, Behnam Ahmadian Baghbaderani, D. Sadi, Leo A. Behie, Ruperto Ulalia, Nao R. Kobayashi, Marcus McLeod
Publikováno v:
Cell Transplantation, Vol 22 (2013)
Huntington's disease (HD) is a neurodegenerative disorder that is characterized by progressive dementia, choreiform involuntary movements, and emotional deterioration. Neuropathological features include the progressive degeneration of striatal γ-ami
Publikováno v:
European Journal of Neuroscience. 27:43-52
Although neural transplantation of fetal dopaminergic cells is a promising therapy for Parkinson's disease, poor transplanted cell survival limits its efficacy. In the present study it was hypothesized that the use of Poloxamer 188 (P188), a non-ioni
Publikováno v:
Neuroscience. 147:712-719
Glial cell-line derived neurotrophic factor (GDNF) enhances dopamine (DA) cell survival and fiber outgrowth, and may be beneficial in enhancing cell restorative strategies for Parkinson's disease (PD). However, GDNF may have different roles for trans
Publikováno v:
Cell Transplantation, Vol 15 (2006)
The development of new cell replacement strategies using neural stem cells (NSC) may provide an alternative and unlimited cell source for clinical neural transplantation in neurodegenerative diseases such as Parkinson's and Huntington's disease. The
Publikováno v:
Cell Transplantation, Vol 13 (2004)
The immunosuppressive drugs tacrolimus (TAC) and rapamycin (RAPA) have both been found to have neuroprotective effects on dopaminergic neurons. The purpose of the present study was to investigate whether liposomal formulations of these drugs administ
Publikováno v:
Cell Transplantation, Vol 11 (2002)
Optimal placement of intrastriatal dopaminergic grafts is likely crucial to optimize clinical recovery in Parkinson's disease (PD). The target sites of dopaminergic grafts vary among clinical trials and may partially explain the variable results in c
Publikováno v:
Experimental Neurology. 172:416-424
The most widely used immunosuppressant in neural transplantation is cyclosporine- A (CsA). However, CsA has significant toxic effects when administered systemically. Tacrolimus (FK506), is a more potent immunosuppressant than CsA and can be prepared